These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 15507502

  • 21. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [Abstract] [Full Text] [Related]

  • 22. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ.
    AIDS; 2007 Apr 23; 21(7):825-34. PubMed ID: 17415037
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
    Madeddu G, Porqueddu EM, Cambosu F, Saba F, Fois AG, Pirina P, Mura MS.
    Infection; 2008 Jun 23; 36(3):231-6. PubMed ID: 18463787
    [Abstract] [Full Text] [Related]

  • 27. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.
    Clin Infect Dis; 2005 Nov 01; 41(9):1326-32. PubMed ID: 16206110
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management.
    Allison GT, Bostrom MP, Glesby MJ.
    AIDS; 2003 Jan 03; 17(1):1-9. PubMed ID: 12478064
    [Abstract] [Full Text] [Related]

  • 31. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.
    Clin Infect Dis; 2006 Jan 01; 42(1):136-44. PubMed ID: 16323104
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V, Red de Investigación en SIDA.
    J Med Virol; 2005 Sep 01; 77(1):23-8. PubMed ID: 16032728
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.